FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Keith Kaufman

Research Profile

Procedures

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Juan Camilo Arjona Ferreira; Nir Barzilai; Gregory T Golm; Hua Guo; Keith D Kaufman; Michel Marre; Christine McCrary Sisk; Barry J Goldstein
Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency.
Juan C Arjona Ferreira; Dalila Corry; Michael J Davies; Gregory T Golm; Edward J Gonzalez; Keith D Kaufman; Carl E Mogensen; Lance Sloan; Lei Xu; Barry J Goldstein
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Vivian Fonseca; Barry J Goldstein; Gregory T Golm; Amy O Johnson-Levonas; Keith D Kaufman; Jerry D Morgan; Yue Shentu; Bart Staels; Helmut Steinberg
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Keith Kaufman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Juan Camilo Arjona Ferreira; Nir Barzilai; Gregory T Golm; Hua Guo; Keith D Kaufman; Michel Marre; Christine McCrary Sisk; Barry J Goldstein
Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency.
Diabetes care 2013;36(5):1067-73.
2013: Juan C Arjona Ferreira; Dalila Corry; Michael J Davies; Gregory T Golm; Edward J Gonzalez; Keith D Kaufman; Carl E Mogensen; Lance Sloan; Lei Xu; Barry J Goldstein
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2013;61(4):579-87.
2013: Vivian Fonseca; Barry J Goldstein; Gregory T Golm; Amy O Johnson-Levonas; Keith D Kaufman; Jerry D Morgan; Yue Shentu; Bart Staels; Helmut Steinberg
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
Journal of diabetes and its complications 2013;27(2):177-83.
2013: Adrian S Dobs; Lorraine Duran; John M Amatruda; Pablo Aschner; Yu Chen; Barry J Goldstein; Gregory T Golm; Julie S Hill; Edward S Horton; Keith D Kaufman; Ronald B Langdon; Guillermo E Umpierrez; Debora E Williams-Herman; Juan Camilo Arjona Ferreira
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Journal of diabetes 2013;5(1):68-79.
2013: Samuel S Engel; Gregory T Golm; Keith D Kaufman; Deborah Shapiro; Michael J Davies; Barry J Goldstein
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Cardiovascular diabetology 2013;12():3.
2012: Wenying Yang; Samuel S Engel; Barry J Goldstein; Yanfen Guan; Amy O Johnson-Levonas; Keith D Kaufman; Zhi Li; Yue Shentu; Maria Alba
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Journal of diabetes 2012;4(3):227-37.
2012: Elise A Olsen; Anthony Rodgers; Jennifer Rotonda; Elizabeth Round; Ronald Savin; David A Whiting; Amy O Johnson-Levonas; Keith D Kaufman
Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo.
Journal of the American Academy of Dermatology 2012;67(3):379-86.
2012: Karl J Krobot; Gary E Meininger; Thomas Seck; Debora Williams-Herman; Michael J Davies; Shannon Allen Ferrante; Keith D Kaufman; Barry J Goldstein
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Current medical research and opinion 2012;28(8):1281-7.
2012: Kun-Ho Yoon; G T Golm; Keith D Kaufman; M Lee; E A O'Neill; H Steinberg; R Teng; B J Goldstein
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Diabetes, obesity & metabolism 2012;14(8):745-52.
2012: J Wainstein; L Xu; S S Engel; G T Golm; S Hussain; L Katz; Keith D Kaufman; E A O'Neill; B J Goldstein
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Diabetes, obesity & metabolism 2012;14(5):409-18.
2011: Gary E Meininger; Russell Scott; Yue Shentu; Keith D Kaufman; Edmund Luo; Maria Alba; Himal Amin; Michael J Davies; Barry J Goldstein
Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes.
Diabetes care 2011;34(12):2560-6.
2011: A Pérez-Monteverde; T Seck; C M Sisk; D E Williams-Herman; L Xu; S S Engel; Keith D Kaufman; M A Lee; B J Goldstein
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
International journal of clinical practice 2011;65(9):930-8.
2011: L Olansky; C Reasner; T L Seck; L Terranella; D E Williams-Herman; M Chen; Keith D Kaufman; A Mehta; B J Goldstein
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Diabetes, obesity & metabolism 2011;13(9):841-9.
2011: Thomas L Seck; Christine McCrary Sisk; Hongwei Wang; Debora E Williams-Herman; Samuel S Engel; Gregory T Golm; Keith D Kaufman; Barry J Goldstein
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Diabetes research and clinical practice 2011;93(1):e15-7.
2011: C Reasner; L Olansky; T L Seck; D E Williams-Herman; M Chen; L Terranella; Amy O Johnson-Levonas; Keith D Kaufman; B J Goldstein
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism 2011;13(7):644-52.
2011: Nir Barzilai; Hua Guo; Erin M Mahoney; Suzanne Caporossi; Gregory T Golm; Ronald B Langdon; Debora Williams-Herman; Keith D Kaufman; John M Amatruda; Barry J Goldstein; Helmut Steinberg
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Current medical research and opinion 2011;27(5):1049-58.
2010: S S Engel; D E Williams-Herman; G T Golm; R J Clay; S V Machotka; Keith D Kaufman; B J Goldstein
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
International journal of clinical practice 2010;64(7):984-90.
2010: D Williams-Herman; J Johnson; R Teng; G Golm; Keith D Kaufman; B J Goldstein; John M Amatruda
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
Diabetes, obesity & metabolism 2010;12(5):442-51.
2010: T Seck; M Nauck; D Sheng; S Sunga; Michael J Davies; P P Stein; Keith D Kaufman; John M Amatruda
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
International journal of clinical practice 2010;64(5):562-76.
2010: Mary F Morrison; Paulette Ceesay; Ira Gantz; Keith D Kaufman; Christopher R Lines
Randomized, controlled, double-blind trial of taranabant for smoking cessation.
Psychopharmacology 2010;209(3):245-53.
2010: Debora Williams-Herman; Samuel S Engel; Elizabeth Round; Jeremy Johnson; Gregory T Golm; Hua Guo; Bret J Musser; Michael J Davies; Keith D Kaufman; Barry J Goldstein
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
BMC endocrine disorders 2010;10():7.
2009: Maria Alba; D Sheng; Y Guan; D Williams-Herman; P Larson; J R Sachs; Nancy A Thornberry; Gary A Herman; Keith D Kaufman; B J Goldstein
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Current medical research and opinion 2009;25(10):2507-14.
2009: Debora Williams-Herman; Jeremy Johnson; Rujun Teng; Edmund Luo; Michael J Davies; Keith D Kaufman; Barry J Goldstein; John M Amatruda
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Current medical research and opinion 2009;25(3):569-83.
2008: Keith D Kaufman; Cynthia J Girman; Elizabeth M Round; Amy O Johnson-Levonas; Arvind K Shah; Jennifer Rotonda
Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients.
European journal of dermatology : EJD 2008;18(4):407-11.
2008: Keith D Kaufman; Jennifer Rotonda; Arvind K Shah; Alan G Meehan
Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss).
European journal of dermatology : EJD 2008;18(4):400-6.
2008: Itamar Raz; Yu Chen; Mei Wu; Shehla Hussain; Keith D Kaufman; John M Amatruda; Ronald B Langdon; Peter P Stein; Maria Alba
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Current medical research and opinion 2008;24(2):537-50.
2006: Vera H Price; Emory Menefee; Matilde Sanchez; Keith D Kaufman
Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results.
Journal of the American Academy of Dermatology 2006;55(1):71-4.
2002: Vera H Price; Emory Menefee; Matilde Sanchez; Patrick Ruane; Keith D Kaufman
Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily.
Journal of the American Academy of Dermatology 2002;46(4):517-23.
2000: Dominique Van Neste; V Fuh; P Sanchez-Pedreno; E Lopez-Bran; H Wolff; David A Whiting; J Roberts; D Kopera; J J Stene; S Calvieri; Antonella Tosti; E Prens; M Guarrera; P Kanojia; W He; Keith D Kaufman
Finasteride increases anagen hair in men with androgenetic alopecia.
The British journal of dermatology 2000;143(4):804-10.
1998: Keith D Kaufman; Elise A Olsen; David A Whiting; Ronald Savin; R DeVillez; Wilma F Bergfeld; Vera H Price; Dominique Van Neste; Janet L Roberts; Maria Hordinsky; J Shapiro; Bruce Binkowitz; Gleen J Gormley
Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Journal of the American Academy of Dermatology 1998;39(4 Pt 1):578-89.